Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s share price reached a new 52-week high on Monday . The company traded as high as $68.73 and last traded at $66.57, with a volume of 327113 shares. The stock had previously closed at $65.00.
Gemini Therapeutics Stock Performance
The company’s 50 day simple moving average is $50.27 and its 200-day simple moving average is $44.19. The firm has a market capitalization of $2.73 billion, a PE ratio of -63.26 and a beta of -0.12.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Featured Stories
- Five stocks we like better than Gemini Therapeutics
- Top Biotech Stocks: Exploring Innovation Opportunities
- Rocket Lab is the Right Stock for the Right Time
- Insider Buying Explained: What Investors Need to Know
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Ride Out The Recession With These Dividend Kings
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
